Buy Rating for Absci: Strategic Advancements and Promising Clinical Trials Highlight Growth Potential

JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on ABSI stock, giving a Buy rating today.

Debanjana Chatterjee has given her Buy rating due to a combination of factors including Absci’s recent advancements and strategic positioning. The company has initiated a Phase 1 trial for ABS-101, targeting inflammatory bowel disease, marking its transition into a clinical-stage biotech. The upcoming interim data expected in the second half of 2025 will provide insights into the safety and efficacy of their antibody design capabilities, which could potentially lead to lucrative partnerships.
Additionally, the planned Phase 1 trial for ABS-201 in androgenetic alopecia, a market with significant unmet needs, is anticipated to start in early 2026. If successful, this could significantly enhance the stock’s value. Furthermore, Absci’s strong cash position and its innovative AI-driven antibody design model, which aligns with regulatory trends towards reducing animal testing, further bolster its potential for future growth and success.

According to TipRanks, Chatterjee is an analyst with an average return of -1.9% and a 28.85% success rate. Chatterjee covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals, Trevi Therapeutics, and EyePoint Pharmaceuticals.

In another report released today, Needham also reiterated a Buy rating on the stock with a $9.00 price target.